Non-interventional study on the Management of Advanced Prostate Cancer with Triptorelin Pamoate Three Month Formulation (PamorelinLA 11.25 mg) or Six Month Formulation (PamorelinLA 22.5 mg) with a Focus on Quality of Life, using the PORPUS Questionnaire (Patient-orientated prostate utility scale).
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2016
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms IQUOPAM
- Sponsors Ipsen Pharma GmbH
- 06 Sep 2012 Status changed from recruiting to completed as reported by German Clinical Trials Register record.
- 06 Jul 2012 Actual initiation date (1 Sep 2011) added as reported by German Clinical Trials Register record.
- 06 Sep 2011 New trial record